{"protocolSection": {"identificationModule": {"nctId": "NCT01922037", "orgStudyIdInfo": {"id": "ML28528"}, "organization": {"fullName": "Hoffmann-La Roche", "class": "INDUSTRY"}, "briefTitle": "A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)", "officialTitle": "A Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab"}, "statusModule": {"statusVerifiedDate": "2017-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-06-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-03-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-03-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-07-12", "studyFirstSubmitQcDate": "2013-08-13", "studyFirstPostDateStruct": {"date": "2013-08-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-11-09", "resultsFirstSubmitQcDate": "2017-11-09", "resultsFirstPostDateStruct": {"date": "2017-12-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-11-09", "lastUpdatePostDateStruct": {"date": "2017-12-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Hoffmann-La Roche", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 806, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Participants With Allergic Asthma", "type": "EXPERIMENTAL", "description": "Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.", "interventionNames": ["Drug: Omalizumab"]}], "interventions": [{"type": "DRUG", "name": "Omalizumab", "description": "Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.", "armGroupLabels": ["Participants With Allergic Asthma"], "otherNames": ["Xolair"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Total Number of Asthma Exacerbations During Months 1-12", "description": "An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/= 3 days.", "timeFrame": "Months 1-12"}], "secondaryOutcomes": [{"measure": "Total Number of Asthma Exacerbations During Months 1-6", "description": "An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/=3 days.", "timeFrame": "Months 1-6"}, {"measure": "Total Number of Asthma Exacerbations During Months 7-12", "description": "An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/= 3 days.", "timeFrame": "Months 7-12"}, {"measure": "Total Number of Asthma-Related Hospital Admissions During Months 1-12", "timeFrame": "Months 1-12"}, {"measure": "Total Number of Asthma-Related Hospital Admissions During Months 1-6", "timeFrame": "Months 1-6"}, {"measure": "Total Number of Asthma-Related Hospital Admissions During Months 7-12", "timeFrame": "Months 7-12"}, {"measure": "Total Number of Asthma-Related ER Visits During Months 1-12", "timeFrame": "Months 1-12"}, {"measure": "Total Number of Asthma-Related Emergency Room (ER) Visits During Months 1-6", "timeFrame": "Months 1-6"}, {"measure": "Total Number of Asthma-Related ER Visits During Months 7-12", "timeFrame": "Months 7-12"}, {"measure": "Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-12", "timeFrame": "Months 1-12"}, {"measure": "Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-6", "timeFrame": "Months 1-6"}, {"measure": "Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 7-12", "timeFrame": "Months 7-12"}, {"measure": "Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-12", "timeFrame": "Months 1-12"}, {"measure": "Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-6", "timeFrame": "Months 1-6"}, {"measure": "Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 7-12", "timeFrame": "Months 7-12"}, {"measure": "Percentage of Participants by Number of Asthma Exacerbations", "description": "Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, \\>/=4) was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/= 3 days.", "timeFrame": "Months 1-12"}, {"measure": "Percentage of Participants by Number of Asthma Exacerbations Requiring Treatment With Systemic Steroids", "description": "Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, \\>/=4) requiring treatment with systemic steroids was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/= 3 days.", "timeFrame": "Months 1-12"}, {"measure": "Change From Baseline in Raw Forced Expiratory Volume in One Second (FEV1)", "description": "FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. Pre-bronchodilator FEV1 and post-bronchodilator FEV1 are reported for each timepoint. FEV1 was measured using spirometry.", "timeFrame": "Baseline, Month 6, end of study (EOS)/early termination (ET) (up to Month 12)"}, {"measure": "Change From Baseline in Raw Forced Vital Capacity (FVC)", "description": "FVC was defined as the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pre-bronchodilator FVC and post-bronchodilator FVC are reported for each timepoint. FVC was measured using spirometry.", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)"}, {"measure": "Change From Baseline in Raw Forced Expiratory Flow at 25-75 Percent (%) of Pulmonary Volume (FEF25%-75%)", "description": "FEF25%-75% was defined as the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Pre-bronchodilator FEF25%-75% and post-bronchodilator FEF25%-75% are reported for each timepoint. FEF25%-75% was measured using spirometry.", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)"}, {"measure": "Change From Baseline in Percentage Predicted FEV1 (ppFEV1)", "description": "FEV1 is the volume of air that can be forced out in one second after taking a deep breath, as measured using spirometry. Hankinson and Wang standards were used to calculate ppFEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. ppFEV1= 100 multiplied by (\\*) FEV1 (in liters \\[L\\]) divided by (/) predicted FEV1 (in L). Pre-bronchodilator ppFEV1 and post-bronchodilator ppFEV1 are reported for each timepoint.", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)"}, {"measure": "Percentage of Participants With Prior Asthma Medications by Category or Class of Medications", "description": "Prior asthma medications were defined as all medications used for asthma prior to the study (initiated within 90 days of baseline) and were assessed retrospectively at baseline. Participants received prior asthma medications of following categories or classes: short acting beta agonist (SABA), combination inhaled corticosteroids/long acting beta agonist (ICS/LABA), leukotriene receptor antagonist (LTRA), inhaled corticosteroids (ICS), oral/parenteral (systemic) corticosteroids, anticholinergic, long acting beta agonist (LABA), and other medication.", "timeFrame": "Baseline"}, {"measure": "Percentage of Participants With Concomitant and Ongoing Asthma Medications by Category or Class of Medications", "description": "Concomitant and ongoing asthma medications were defined as all medications used for asthma which began on or after the participant's study start, as well as those ongoing at the beginning of the study. Participants received following categories or classes of concomitant and ongoing asthma medications: SABA, combination ICS/LABA, LTRA, oral/parenteral (systemic) corticosteroids, ICS, anticholinergic, LABA, and other medication.", "timeFrame": "Baseline until EOS/ET (up to Month 12)"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12) Overall Score", "description": "AQLQ +12 is a 32-item disease specific questionnaire designed to assess the participants' asthma-specific health-related quality of life (QOL). The questionnaire contains four domains: activity limitations (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). All items are scored on a 7-point likert scale. All item scores are averaged to produce one overall QOL score. Overall score ranges from 1 (total impairment) to 7 (no impairment), with higher scores indicating better QOL. A positive change from baseline indicated improved QOL.", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)"}, {"measure": "Change From Baseline in Asthma Control Test (ACT) Overall Score", "description": "Multidimensional factors associated with asthma control from the participant's perspective were assessed using the ACT questionnaire. The ACT is a validated, five-item patient-reported outcome (PRO) questionnaire that measures the impact of asthma on home and work activities, shortness of breath, symptoms, rescue medication usage, and overall asthma control. All items are scored on a 5-point likert scale (1 to 5). All item scores are added together to calculate a total score. Total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. A positive change from baseline indicated improvement.", "timeFrame": "Baseline, Months 3, 6, 9, 12"}, {"measure": "Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score", "description": "WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity. A negative change in score indicated improvement and a positive change indicated impairment.", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)"}, {"measure": "Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using Global Evaluation of Treatment Effectiveness (GETE) by Inversigator", "description": "Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by investigator, is reported.", "timeFrame": "EOS/ET (up to Month 12)"}, {"measure": "Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using GETE by Participant", "description": "Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by participant, is reported.", "timeFrame": "EOS/ET (up to Month 12)"}, {"measure": "Change From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Overall Quality of Life Score", "description": "The MiniRQLQ is a shorter version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) instrument. The MiniRQLQ is a validated quality of life questionnaire to measure the functional impairments that are most troublesome to adult participants with either seasonal or perennial rhinoconjunctivitis of either allergic or non-allergic origin. The miniRQLQ contains 14 items; each item scored on a 7-point scale ranging from 0 \\[not impaired at all\\] to 6 \\[severely impaired\\]). The overall quality of life score is the average of the all item scores and ranges from 0 (not impaired at all) to 6 (severely impaired), with higher scores indicating more impairment. A negative change in score indicated improvement and a positive change indicated impairment.", "timeFrame": "Baseline, EOS/ET (up to Month 12)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants identified by the investigator as a candidate for treatment for asthma with omalizumab\n* Confirmation of access to omalizumab through insurance or other source of funding\n\nExclusion Criteria:\n\n* Enrollment in any other concurrent clinical trial or observational study\n* Participants for whom omalizumab treatment is contraindicated\n* Participants who had a prior allergic reaction to omalizumab or its excipients\n* Participants treated with omalizumab within the previous year\n* Participants who received an experimental drug as part of another study within 3 months of enrollment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Trials", "affiliation": "Hoffmann-La Roche", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Alabama Allergy & Asthma", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Achieve Clinical Research, LLC", "city": "Birmingham", "state": "Alabama", "zip": "35216", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Huntsville Lung Associates PC", "city": "Huntsville", "state": "Alabama", "zip": "35801", "country": "United States", "geoPoint": {"lat": 34.7304, "lon": -86.58594}}, {"facility": "San Tan Allergy & Asthma", "city": "Gilbert", "state": "Arizona", "zip": "85234-2966", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "Dedicated Clinical Research", "city": "Goodyear", "state": "Arizona", "zip": "85395", "country": "United States", "geoPoint": {"lat": 33.43532, "lon": -112.35821}}, {"facility": "Allergy Associates of Tucson", "city": "Tucson", "state": "Arizona", "zip": "85716", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "University of Arizona", "city": "Tucson", "state": "Arizona", "zip": "85724-5030", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Little Rock Allergy & Asthma; Clinical Research Center", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Stuart Epstein MD - PP", "city": "Beverly Hills", "state": "California", "zip": "90212", "country": "United States", "geoPoint": {"lat": 34.07362, "lon": -118.40036}}, {"facility": "West Coast Clinical Trials Global, LLC", "city": "Costa Mesa", "state": "California", "zip": "92626", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Peninsula Allergy Associates", "city": "Daly City", "state": "California", "zip": "94015", "country": "United States", "geoPoint": {"lat": 37.70577, "lon": -122.46192}}, {"facility": "Allianz Medical and Research Center", "city": "Fountain Valley", "state": "California", "zip": "92708", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "William Ebbeling MD - PP", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Gettysburg Medical Clinic", "city": "Fresno", "state": "California", "zip": "93726", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Allergy & Asthma Inst Valley", "city": "Granada Hills", "state": "California", "zip": "91344", "country": "United States", "geoPoint": {"lat": 34.26472, "lon": -118.52314}}, {"facility": "VA Loma Linda Healthcare System", "city": "Loma Linda", "state": "California", "zip": "92357", "country": "United States", "geoPoint": {"lat": 34.04835, "lon": -117.26115}}, {"facility": "Allergy Asthma Care Ctr, Inc.", "city": "Los Angeles", "state": "California", "zip": "90064", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Southern California Research Center", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "North Bay Allergy & Asthma; Medical Assoc", "city": "Napa", "state": "California", "zip": "94558", "country": "United States", "geoPoint": {"lat": 38.29714, "lon": -122.28553}}, {"facility": "Choc Psf, Amc", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Clinical Trials of Orange County", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "California Allergy & Asthma Medical Group, Inc.", "city": "Palmdale", "state": "California", "zip": "93551", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Joann Blessing-Moore MD - PP", "city": "Palo Alto", "state": "California", "zip": "94304", "country": "United States", "geoPoint": {"lat": 37.44188, "lon": -122.14302}}, {"facility": "TPMG - Rancho Cordova", "city": "Rancho Cordova", "state": "California", "zip": "95762", "country": "United States", "geoPoint": {"lat": 38.58907, "lon": -121.30273}}, {"facility": "Redding Allergy & Asthma Care", "city": "Redding", "state": "California", "zip": "96003", "country": "United States", "geoPoint": {"lat": 40.58654, "lon": -122.39168}}, {"facility": "Allergy & Asthma Consultants", "city": "Redwood City", "state": "California", "zip": "94063", "country": "United States", "geoPoint": {"lat": 37.48522, "lon": -122.23635}}, {"facility": "Capital Allergy Resp Dis Ctr", "city": "Sacramento", "state": "California", "zip": "95819", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Central Coast Allergy and Asthma", "city": "Salinas", "state": "California", "zip": "93901", "country": "United States", "geoPoint": {"lat": 36.67774, "lon": -121.6555}}, {"facility": "Allergy Assoc Medical Group", "city": "San Diego", "state": "California", "zip": "92108", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Kaiser Permanente - San Diego", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "University of California at San Francisco", "city": "San Francisco", "state": "California", "zip": "94115", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "Asthma & Allergy Clinic", "city": "San Francisco", "state": "California", "zip": "94121", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "The Allergy and Asthma Clinic", "city": "San Mateo", "state": "California", "zip": "94401", "country": "United States", "geoPoint": {"lat": 37.56299, "lon": -122.32553}}, {"facility": "Allergy & Asthma Medical Group; Clinical Research Division", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "IMMUNOe International Research Centers", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Danbury Hospital", "city": "Danbury", "state": "Connecticut", "zip": "06810", "country": "United States", "geoPoint": {"lat": 41.39482, "lon": -73.45401}}, {"facility": "Christopher C Randolph MD - PP", "city": "Waterbury", "state": "Connecticut", "zip": "06708", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"facility": "Waterbury Pulmonary Associates", "city": "Waterbury", "state": "Connecticut", "zip": "06708", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"facility": "St. Francis Sleep; Allergy & Lung Institute", "city": "Clearwater", "state": "Florida", "zip": "33765", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "AAADRS; Clinical Research Center", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Allergy Asthma & Immun Center", "city": "Leesburg", "state": "Florida", "zip": "34788", "country": "United States", "geoPoint": {"lat": 28.81082, "lon": -81.87786}}, {"facility": "Florida Ctr-Allergy & Asthma", "city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "FL Ctr Allergy & Asthma Res", "city": "Miami", "state": "Florida", "zip": "33176", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Allergy & Asthma Care of FL; Clinical Research", "city": "Ocala", "state": "Florida", "zip": "34471", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"facility": "Central Florida Pulmonary Grou", "city": "Orlando", "state": "Florida", "zip": "32803", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Allergy Asthma & Sinus Center", "city": "Palm Beach Gardens", "state": "Florida", "zip": "33410", "country": "United States", "geoPoint": {"lat": 26.82339, "lon": -80.13865}}, {"facility": "Gulf Coast Allergy Center, P.A.", "city": "Port Charlotte", "state": "Florida", "zip": "33952", "country": "United States", "geoPoint": {"lat": 26.97617, "lon": -82.09064}}, {"facility": "USF Asthma Allergy & Immun; Clinical Research", "city": "Tampa", "state": "Florida", "zip": "33613", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Georgia Pollens", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Brookstone Clinical Res Ctr", "city": "Columbus", "state": "Georgia", "zip": "31904", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "Allergy & Asthma Care Center", "city": "Gainesville", "state": "Georgia", "zip": "30501", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Aeroallergy Research Labs", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Asthma & Allergy of Idaho", "city": "Twin Falls", "state": "Idaho", "zip": "83301", "country": "United States", "geoPoint": {"lat": 42.56297, "lon": -114.46087}}, {"facility": "Rush University Medical Center", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Chest Medicine Consultants", "city": "Chicago", "state": "Illinois", "zip": "60657", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Allergy & Asthma Care LTD", "city": "Glen Carbon", "state": "Illinois", "zip": "62034", "country": "United States", "geoPoint": {"lat": 38.74838, "lon": -89.98316}}, {"facility": "Sneeze Wheeze and Itch Associates LLC", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Allergy Asthma Care", "city": "Crown Point", "state": "Indiana", "zip": "46307", "country": "United States", "geoPoint": {"lat": 41.41698, "lon": -87.36531}}, {"facility": "The Allergy and Asthma Center", "city": "Fort Wayne", "state": "Indiana", "zip": "46804", "country": "United States", "geoPoint": {"lat": 41.1306, "lon": -85.12886}}, {"facility": "Clinical Research Center of Indiana", "city": "Indianapolis", "state": "Indiana", "zip": "46208", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "University of Kansas Med Ctr; Int med/Allgy/Immun/Rheum", "city": "Kansas City", "state": "Kansas", "zip": "66160-7350", "country": "United States", "geoPoint": {"lat": 39.11417, "lon": -94.62746}}, {"facility": "Kansas City Allergy And Asthma Assoc.", "city": "Overland Park", "state": "Kansas", "zip": "66210", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "Abraham Research PLLC", "city": "Florence", "state": "Kentucky", "zip": "41042", "country": "United States", "geoPoint": {"lat": 38.99895, "lon": -84.62661}}, {"facility": "Allergy & Asth Phys of Cent KY", "city": "Lexington", "state": "Kentucky", "zip": "40503", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Dr. Paul Shapero", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Chesapeake Clinical Research Inc - CRN", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Glenn M. Silber, M.D., P.A", "city": "Ellicott City", "state": "Maryland", "zip": "21042", "country": "United States", "geoPoint": {"lat": 39.26733, "lon": -76.79831}}, {"facility": "Family Allergy & Asthma", "city": "Gaithersburg", "state": "Maryland", "zip": "20878", "country": "United States", "geoPoint": {"lat": 39.14344, "lon": -77.20137}}, {"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "98410", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Center for Clinical Research.", "city": "Brockton", "state": "Massachusetts", "zip": "02301", "country": "United States", "geoPoint": {"lat": 42.08343, "lon": -71.01838}}, {"facility": "Allergy Arth Fam Treatment Ctr", "city": "Gardner", "state": "Massachusetts", "zip": "01440", "country": "United States", "geoPoint": {"lat": 42.57509, "lon": -71.99813}}, {"facility": "Infinity Medical Research Inc", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "McGovern & Baja Allergy Assoc", "city": "Springfield", "state": "Massachusetts", "zip": "01103", "country": "United States", "geoPoint": {"lat": 42.10148, "lon": -72.58981}}, {"facility": "Asthma & Allergy Inst of MI", "city": "Clinton Township", "state": "Michigan", "zip": "48038", "country": "United States", "geoPoint": {"lat": 42.58698, "lon": -82.91992}}, {"facility": "Asthma Allergy Ctr of SW MI", "city": "Portage", "state": "Michigan", "zip": "49024", "country": "United States", "geoPoint": {"lat": 42.20115, "lon": -85.58}}, {"facility": "Clinical Research Inst", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Mayo Clinic", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Washington Univ. School of Med", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Impact Clinical Trials", "city": "Las Vegas", "state": "Nevada", "zip": "89106", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Ocean Allergy & Resp Res Ctr", "city": "Brick Township", "state": "New Jersey", "zip": "08724", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"facility": "Adult Ped Aller Central Jersey", "city": "Edison", "state": "New Jersey", "zip": "08820", "country": "United States", "geoPoint": {"lat": 40.51872, "lon": -74.4121}}, {"facility": "Center for Asthma and Allergy", "city": "Highland Park", "state": "New Jersey", "zip": "08904", "country": "United States", "geoPoint": {"lat": 40.49594, "lon": -74.42432}}, {"facility": "Atlantic Allergy Asthma Immunology Associates", "city": "Ocean City", "state": "New Jersey", "zip": "07712", "country": "United States", "geoPoint": {"lat": 39.27762, "lon": -74.5746}}, {"facility": "Allergy Treatment Center of New Jersey", "city": "Piscataway", "state": "New Jersey", "zip": "08854", "country": "United States", "geoPoint": {"lat": 40.49927, "lon": -74.39904}}, {"facility": "Pulmonary and Allergy Associates", "city": "Summit", "state": "New Jersey", "zip": "07901", "country": "United States", "geoPoint": {"lat": 40.71562, "lon": -74.36468}}, {"facility": "Allergy Consultants, PA", "city": "Verona", "state": "New Jersey", "zip": "07044", "country": "United States", "geoPoint": {"lat": 40.82982, "lon": -74.24015}}, {"facility": "SUNY Downstate Medical Center.", "city": "Brooklyn", "state": "New York", "zip": "11203", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Boris Sagalovich MD - PC", "city": "Brooklyn", "state": "New York", "zip": "11229", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Island Medical Research Pc", "city": "Commack", "state": "New York", "zip": "11725", "country": "United States", "geoPoint": {"lat": 40.84288, "lon": -73.29289}}, {"facility": "North Shore Medical Arts, LLP", "city": "Great Neck", "state": "New York", "zip": "11021", "country": "United States", "geoPoint": {"lat": 40.80066, "lon": -73.72846}}, {"facility": "Jamaica Hospital Medical Center", "city": "Jamaica", "state": "New York", "zip": "11418", "country": "United States", "geoPoint": {"lat": 40.69149, "lon": -73.80569}}, {"facility": "Winthrop Univ Hospital", "city": "Mineola", "state": "New York", "zip": "11501", "country": "United States", "geoPoint": {"lat": 40.74927, "lon": -73.64068}}, {"facility": "Laura and ISAAC Perlmutter Cancer Center at NYU Langone.", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Parikh Institute for Research LLC", "city": "New York", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Albert P Hirdt DO - PP", "city": "Newburgh", "state": "New York", "zip": "12550", "country": "United States", "geoPoint": {"lat": 41.50343, "lon": -74.01042}}, {"facility": "Olean Medical Group", "city": "Olean", "state": "New York", "zip": "14760", "country": "United States", "geoPoint": {"lat": 42.07756, "lon": -78.42974}}, {"facility": "University of Rochester", "city": "Rochester", "state": "New York", "zip": "14618", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Advanced Allergy & Asthma PLLC", "city": "Rockville Center", "state": "New York", "zip": "11570", "country": "United States"}, {"facility": "Urban Health Plan, Inc.", "city": "The Bronx", "state": "New York", "zip": "10459", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Montefiore Medical Center", "city": "The Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Alan Kaufman MD - PP", "city": "The Bronx", "state": "New York", "zip": "10465", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Allergy Partners of Western NC", "city": "Asheville", "state": "North Carolina", "zip": "28801", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "Allergy & Asthma Centre of Dayton", "city": "Centerville", "state": "Ohio", "zip": "45458", "country": "United States", "geoPoint": {"lat": 39.62839, "lon": -84.15938}}, {"facility": "The Cleveland Clinic Foundation", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Santiago Reyes MD-Private Prac", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Vital Prospects Clin Res Pc", "city": "Tulsa", "state": "Oklahoma", "zip": "74136", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Bend Memorial Clinic", "city": "Bend", "state": "Oregon", "zip": "97701", "country": "United States", "geoPoint": {"lat": 44.05817, "lon": -121.31531}}, {"facility": "Central PA Asth & Allergy Care; Research Division", "city": "Altoona", "state": "Pennsylvania", "zip": "16601", "country": "United States", "geoPoint": {"lat": 40.51868, "lon": -78.39474}}, {"facility": "Allergy and Asthmas; Specialists of Harrisburg", "city": "Harrisburg", "state": "Pennsylvania", "zip": "17110", "country": "United States", "geoPoint": {"lat": 40.2737, "lon": -76.88442}}, {"facility": "Penn State Hershey Medical Group", "city": "Hershey", "state": "Pennsylvania", "zip": "17033", "country": "United States", "geoPoint": {"lat": 40.28592, "lon": -76.65025}}, {"facility": "Inst for Resp & Sleep Med PC", "city": "Langhorne", "state": "Pennsylvania", "zip": "19047", "country": "United States", "geoPoint": {"lat": 40.17455, "lon": -74.92267}}, {"facility": "Allergy and Asthma Research of NJ, lnc", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19115", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Allergy & Clinical Immun Assoc", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15241", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "South Hills Pulmonary Assoc", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15243", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Respiratory Specialists", "city": "Reading", "state": "Pennsylvania", "zip": "19610", "country": "United States", "geoPoint": {"lat": 40.33565, "lon": -75.92687}}, {"facility": "Nat'l Aller Asth-Charleston", "city": "Charleston", "state": "South Carolina", "zip": "29406", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "ADAC Research PA", "city": "Greenville", "state": "South Carolina", "zip": "29607", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Upstate Pharma Research", "city": "Simpsonville", "state": "South Carolina", "zip": "29681", "country": "United States", "geoPoint": {"lat": 34.73706, "lon": -82.25428}}, {"facility": "East Tennessee Center for Clinical Research", "city": "Knoxville", "state": "Tennessee", "zip": "37909", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"facility": "LeBonheur Children's Hospital", "city": "Memphis", "state": "Tennessee", "zip": "38103", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Vanderbilt Medical University", "city": "Nashville", "state": "Tennessee", "zip": "37203", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Greater Austin Allergy Asthma and Immunology", "city": "Austin", "state": "Texas", "zip": "78746", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Elliot J. Ginchansky, MD, PA", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Allergy Asthma Research Assoc", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "University of Texas Medical Branch;Division of APICS", "city": "Galveston", "state": "Texas", "zip": "77555", "country": "United States", "geoPoint": {"lat": 29.30135, "lon": -94.7977}}, {"facility": "Allergy Asthma & Immun Assoc", "city": "Garland", "state": "Texas", "zip": "75044", "country": "United States", "geoPoint": {"lat": 32.91262, "lon": -96.63888}}, {"facility": "Live Oak Allergy & Asthma Clinic", "city": "San Antonio", "state": "Texas", "zip": "78233", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Allergy & Asthma Res Ctr PA", "city": "San Antonio", "state": "Texas", "zip": "78251", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Sugar Land Allerg Asthma Immun", "city": "Sugar Land", "state": "Texas", "zip": "77479", "country": "United States", "geoPoint": {"lat": 29.61968, "lon": -95.63495}}, {"facility": "University of Texas Health Center at Tyler", "city": "Tyler", "state": "Texas", "zip": "75708", "country": "United States", "geoPoint": {"lat": 32.35126, "lon": -95.30106}}, {"facility": "Allergy Associates of Utah", "city": "Murray", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "Bridgerland Clinical Research", "city": "North Logan", "state": "Utah", "zip": "84341", "country": "United States", "geoPoint": {"lat": 41.76937, "lon": -111.80467}}, {"facility": "Pulmonary Research of Albingdon", "city": "Abingdon", "state": "Virginia", "zip": "24210", "country": "United States", "geoPoint": {"lat": 36.70983, "lon": -81.97735}}, {"facility": "O & O Alpan, LLC", "city": "Fairfax", "state": "Virginia", "zip": "22030", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Clinical Research Partners, LLC", "city": "Henrico", "state": "Virginia", "zip": "23233", "country": "United States", "geoPoint": {"lat": 36.59264, "lon": -78.61611}}, {"facility": "Allergy Asthma & Sinus Center", "city": "Leesburg", "state": "Virginia", "zip": "20176", "country": "United States", "geoPoint": {"lat": 39.11566, "lon": -77.5636}}, {"facility": "Children's Hospital of the King's Daughter", "city": "Norfolk", "state": "Virginia", "zip": "23510", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Bellingham Asthma, Allergy & Immunology", "city": "Bellingham", "state": "Washington", "zip": "98225", "country": "United States", "geoPoint": {"lat": 48.75955, "lon": -122.48822}}, {"facility": "ASTHMA, Inc", "city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Pulmonary & Sleep Research", "city": "Spokane", "state": "Washington", "zip": "99204", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Northwest Asthma Allergy Center", "city": "Vancouver", "state": "Washington", "zip": "98664", "country": "United States", "geoPoint": {"lat": 45.63873, "lon": -122.66149}}, {"facility": "Allergy Asthma & Sinus Center", "city": "Greenfield", "state": "Wisconsin", "zip": "53228", "country": "United States", "geoPoint": {"lat": 42.9614, "lon": -88.01259}}, {"facility": "Dean Clinic", "city": "Madison", "state": "Wisconsin", "zip": "53715", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "University of Wisconsin;Allergy & Asthma Clinical Research", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Medical College of Wisconsin", "city": "Milwaukee", "state": "Wisconsin", "zip": "53226", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}]}, "referencesModule": {"references": [{"pmid": "35526776", "type": "DERIVED", "citation": "DeLeon S, Barsanti F, Holweg CTJ, Yoo B, Creasy B, Wechsler ME. Omalizumab treatment reduces asthma exacerbations regardless of airway bronchodilator reversibility. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2181-2183.e1. doi: 10.1016/j.jaip.2022.04.029. Epub 2022 May 6. No abstract available."}, {"pmid": "33838339", "type": "DERIVED", "citation": "Soong W, Yoo B, Pazwash H, Holweg CTJ, Casale TB. Omalizumab response in patients with asthma by number and type of allergen. Ann Allergy Asthma Immunol. 2021 Aug;127(2):223-231. doi: 10.1016/j.anai.2021.04.002. Epub 2021 Apr 8."}, {"pmid": "33465457", "type": "DERIVED", "citation": "Chen M, Choo E, Yoo B, Raut P, Haselkorn T, Pazwash H, Holweg CTJ, Hudes G. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities. Ann Allergy Asthma Immunol. 2021 Jun;126(6):666-673. doi: 10.1016/j.anai.2021.01.015. Epub 2021 Jan 17."}, {"pmid": "33217063", "type": "DERIVED", "citation": "Chen M, Shepard K 2nd, Yang M, Raut P, Pazwash H, Holweg CTJ, Choo E. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021 Apr;51(4):546-555. doi: 10.1111/cea.13790. Epub 2021 Jan 7."}, {"pmid": "31981731", "type": "DERIVED", "citation": "Hanania NA, Djukanovic R, Heaney LG, Yang M, Yoo B, Iqbal A, Griffin NM, Chipps BE. Determinants of lung function improvement with omalizumab in adults with allergic asthma. J Allergy Clin Immunol Pract. 2020 Jun;8(6):2068-2070. doi: 10.1016/j.jaip.2020.01.019. Epub 2020 Jan 22. No abstract available."}, {"pmid": "30576755", "type": "DERIVED", "citation": "Hanania NA, Chipps BE, Griffin NM, Yoo B, Iqbal A, Casale TB. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019 Apr;143(4):1629-1633.e2. doi: 10.1016/j.jaci.2018.11.032. Epub 2018 Dec 18. No abstract available."}, {"pmid": "29421314", "type": "DERIVED", "citation": "Luskin AT, Chipps BE, Casale TB, Griffin NM. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2018 May;120(5):549-550. doi: 10.1016/j.anai.2018.01.034. Epub 2018 Feb 5. No abstract available."}, {"pmid": "29054589", "type": "DERIVED", "citation": "Chipps BE, Zeiger RS, Luskin AT, Busse WW, Trzaskoma BL, Antonova EN, Pazwash H, Limb SL, Solari PG, Griffin NM, Casale TB. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017 Dec;119(6):524-532.e2. doi: 10.1016/j.anai.2017.09.056. Epub 2017 Oct 18."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Results are reported by age group (adult participants and adolescent participants) as well as for all participants.", "groups": [{"id": "FG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "FG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age greater than or equal to \\[\\>/=18\\] years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "737"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "732"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "563"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "174"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Participant non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "46"}]}, {"type": "Investigator/Sponsor decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Other unspecified", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "66"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All enrolled participants", "groups": [{"id": "BG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "BG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "737"}, {"groupId": "BG002", "value": "806"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.0", "spread": "1.69"}, {"groupId": "BG001", "value": "50.4", "spread": "14.75"}, {"groupId": "BG002", "value": "47.3", "spread": "17.40"}]}]}]}, {"title": "Sex: Female, Male", "populationDescription": "All enrolled participants", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "487"}, {"groupId": "BG002", "value": "512"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "250"}, {"groupId": "BG002", "value": "294"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Total Number of Asthma Exacerbations During Months 1-12", "description": "An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/= 3 days.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma exacerbations", "timeFrame": "Months 1-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "727"}, {"groupId": "OG002", "value": "796"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "spread": "0.815"}, {"groupId": "OG001", "value": "0.81", "spread": "1.407"}, {"groupId": "OG002", "value": "0.78", "spread": "1.369"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma Exacerbations During Months 1-6", "description": "An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/=3 days.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma exacerbations", "timeFrame": "Months 1-6", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "726"}, {"groupId": "OG002", "value": "795"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "spread": "0.440"}, {"groupId": "OG001", "value": "0.51", "spread": "0.988"}, {"groupId": "OG002", "value": "0.48", "spread": "0.957"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma Exacerbations During Months 7-12", "description": "An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/= 3 days.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma exacerbations", "timeFrame": "Months 7-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "635"}, {"groupId": "OG002", "value": "698"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.29", "spread": "0.521"}, {"groupId": "OG001", "value": "0.35", "spread": "0.756"}, {"groupId": "OG002", "value": "0.35", "spread": "0.738"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Hospital Admissions During Months 1-12", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related hospital admissions", "timeFrame": "Months 1-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "727"}, {"groupId": "OG002", "value": "796"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "spread": "0.205"}, {"groupId": "OG001", "value": "0.06", "spread": "0.356"}, {"groupId": "OG002", "value": "0.06", "spread": "0.346"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Hospital Admissions During Months 1-6", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related hospital admissions", "timeFrame": "Months 1-6", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "726"}, {"groupId": "OG002", "value": "795"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "0.169"}, {"groupId": "OG001", "value": "0.03", "spread": "0.230"}, {"groupId": "OG002", "value": "0.03", "spread": "0.225"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Hospital Admissions During Months 7-12", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related hospital admissions", "timeFrame": "Months 7-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "635"}, {"groupId": "OG002", "value": "698"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.126"}, {"groupId": "OG001", "value": "0.03", "spread": "0.215"}, {"groupId": "OG002", "value": "0.03", "spread": "0.208"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related ER Visits During Months 1-12", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related ER visits", "timeFrame": "Months 1-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "727"}, {"groupId": "OG002", "value": "796"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.380"}, {"groupId": "OG001", "value": "0.14", "spread": "0.575"}, {"groupId": "OG002", "value": "0.14", "spread": "0.560"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Emergency Room (ER) Visits During Months 1-6", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related ER visits", "timeFrame": "Months 1-6", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "726"}, {"groupId": "OG002", "value": "795"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "spread": "0.205"}, {"groupId": "OG001", "value": "0.09", "spread": "0.410"}, {"groupId": "OG002", "value": "0.09", "spread": "0.397"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related ER Visits During Months 7-12", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related ER visits", "timeFrame": "Months 7-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "635"}, {"groupId": "OG002", "value": "698"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "spread": "0.296"}, {"groupId": "OG001", "value": "0.06", "spread": "0.293"}, {"groupId": "OG002", "value": "0.06", "spread": "0.294"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-12", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related physician's office visits", "timeFrame": "Months 1-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "727"}, {"groupId": "OG002", "value": "796"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.39", "spread": "0.771"}, {"groupId": "OG001", "value": "0.39", "spread": "0.866"}, {"groupId": "OG002", "value": "0.39", "spread": "0.858"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-6", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related physician's office visits", "timeFrame": "Months 1-6", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "726"}, {"groupId": "OG002", "value": "795"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.23", "spread": "0.598"}, {"groupId": "OG001", "value": "0.23", "spread": "0.584"}, {"groupId": "OG002", "value": "0.23", "spread": "0.585"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 7-12", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related physician's office visits", "timeFrame": "Months 7-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "635"}, {"groupId": "OG002", "value": "698"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.423"}, {"groupId": "OG001", "value": "0.18", "spread": "0.515"}, {"groupId": "OG002", "value": "0.18", "spread": "0.507"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-12", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related telephone calls", "timeFrame": "Months 1-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "727"}, {"groupId": "OG002", "value": "796"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.35", "spread": "0.783"}, {"groupId": "OG001", "value": "0.43", "spread": "1.181"}, {"groupId": "OG002", "value": "0.43", "spread": "1.152"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-6", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related telephone calls", "timeFrame": "Months 1-6", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "726"}, {"groupId": "OG002", "value": "795"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.407"}, {"groupId": "OG001", "value": "0.24", "spread": "0.799"}, {"groupId": "OG002", "value": "0.23", "spread": "0.773"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 7-12", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "asthma-related telephone calls", "timeFrame": "Months 7-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "635"}, {"groupId": "OG002", "value": "698"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.21", "spread": "0.544"}, {"groupId": "OG001", "value": "0.22", "spread": "0.692"}, {"groupId": "OG002", "value": "0.22", "spread": "0.680"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants by Number of Asthma Exacerbations", "description": "Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, \\>/=4) was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/= 3 days.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Months 1-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "727"}, {"groupId": "OG002", "value": "796"}]}], "classes": [{"title": "No (0) Asthma Exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "69.6"}, {"groupId": "OG001", "value": "61.8"}, {"groupId": "OG002", "value": "62.4"}]}]}, {"title": "1 Asthma Exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "18.8"}, {"groupId": "OG001", "value": "18.3"}, {"groupId": "OG002", "value": "18.3"}]}]}, {"title": "2 Asthma Exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.2"}, {"groupId": "OG001", "value": "9.2"}, {"groupId": "OG002", "value": "9.0"}]}]}, {"title": "3 Asthma Exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3"}, {"groupId": "OG001", "value": "4.3"}, {"groupId": "OG002", "value": "4.3"}]}]}, {"title": ">/=4 Asthma Exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "6.5"}, {"groupId": "OG002", "value": "5.9"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants by Number of Asthma Exacerbations Requiring Treatment With Systemic Steroids", "description": "Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, \\>/=4) requiring treatment with systemic steroids was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \\>/= 3 days.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Months 1-12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "727"}, {"groupId": "OG002", "value": "796"}]}], "classes": [{"title": "No (0) Asthma Exacerbation Requiring Treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.0"}, {"groupId": "OG001", "value": "62.3"}, {"groupId": "OG002", "value": "63.1"}]}]}, {"title": "1 Asthma Exacerbation Requiring Treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.3"}, {"groupId": "OG001", "value": "18.2"}, {"groupId": "OG002", "value": "18.3"}]}]}, {"title": "2 Asthma Exacerbations Requiring Treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3"}, {"groupId": "OG001", "value": "9.4"}, {"groupId": "OG002", "value": "8.9"}]}]}, {"title": "3 Asthma Exacerbations Requiring Treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3"}, {"groupId": "OG001", "value": "4.5"}, {"groupId": "OG002", "value": "4.5"}]}]}, {"title": ">/=4 Asthma Exacerbations Requiring Treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "5.6"}, {"groupId": "OG002", "value": "5.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Raw Forced Expiratory Volume in One Second (FEV1)", "description": "FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. Pre-bronchodilator FEV1 and post-bronchodilator FEV1 are reported for each timepoint. FEV1 was measured using spirometry.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline, Month 6, end of study (EOS)/early termination (ET) (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "728"}, {"groupId": "OG002", "value": "795"}]}], "classes": [{"title": "Baseline: Pre-bronchodilator FEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "728"}, {"groupId": "OG002", "value": "795"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.61", "spread": "0.736"}, {"groupId": "OG001", "value": "2.24", "spread": "0.820"}, {"groupId": "OG002", "value": "2.27", "spread": "0.819"}]}]}, {"title": "Change at Month 6: Pre-bronchodilator FEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "568"}, {"groupId": "OG002", "value": "626"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "spread": "0.402"}, {"groupId": "OG001", "value": "0.06", "spread": "0.359"}, {"groupId": "OG002", "value": "0.06", "spread": "0.363"}]}]}, {"title": "Change at EOS/ET: Pre-bronchodilator FEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "573"}, {"groupId": "OG002", "value": "630"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.463"}, {"groupId": "OG001", "value": "0.03", "spread": "0.378"}, {"groupId": "OG002", "value": "0.04", "spread": "0.388"}]}]}, {"title": "Baseline: Post-bronchodilator FEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "713"}, {"groupId": "OG002", "value": "778"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.79", "spread": "0.767"}, {"groupId": "OG001", "value": "2.38", "spread": "0.810"}, {"groupId": "OG002", "value": "2.41", "spread": "0.814"}]}]}, {"title": "Change at Month 6: Post-bronchodilator FEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "523"}, {"groupId": "OG002", "value": "577"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.522"}, {"groupId": "OG001", "value": "0.04", "spread": "0.286"}, {"groupId": "OG002", "value": "0.05", "spread": "0.315"}]}]}, {"title": "Change at EOS/ET: Post-bronchodilator FEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "534"}, {"groupId": "OG002", "value": "586"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.18", "spread": "0.446"}, {"groupId": "OG001", "value": "0.02", "spread": "0.322"}, {"groupId": "OG002", "value": "0.03", "spread": "0.338"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Raw Forced Vital Capacity (FVC)", "description": "FVC was defined as the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pre-bronchodilator FVC and post-bronchodilator FVC are reported for each timepoint. FVC was measured using spirometry.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "728"}, {"groupId": "OG002", "value": "795"}]}], "classes": [{"title": "Baseline: Pre-bronchodilator FVC", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "728"}, {"groupId": "OG002", "value": "795"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.36", "spread": "0.842"}, {"groupId": "OG001", "value": "3.08", "spread": "0.987"}, {"groupId": "OG002", "value": "3.11", "spread": "0.978"}]}]}, {"title": "Change at Month 6: Pre-bronchodilator FVC", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "568"}, {"groupId": "OG002", "value": "625"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "spread": "0.380"}, {"groupId": "OG001", "value": "0.07", "spread": "0.562"}, {"groupId": "OG002", "value": "0.07", "spread": "0.548"}]}]}, {"title": "Change at EOS/ET: Pre-bronchodilator FVC", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "572"}, {"groupId": "OG002", "value": "629"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.22", "spread": "0.321"}, {"groupId": "OG001", "value": "0.03", "spread": "0.417"}, {"groupId": "OG002", "value": "0.04", "spread": "0.413"}]}]}, {"title": "Baseline: Post-bronchodilator FVC", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "713"}, {"groupId": "OG002", "value": "778"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.43", "spread": "0.878"}, {"groupId": "OG001", "value": "3.19", "spread": "0.959"}, {"groupId": "OG002", "value": "3.21", "spread": "0.954"}]}]}, {"title": "Change at Month 6: Post-bronchodilator FVC", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "523"}, {"groupId": "OG002", "value": "576"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.324"}, {"groupId": "OG001", "value": "0.07", "spread": "0.661"}, {"groupId": "OG002", "value": "0.07", "spread": "0.637"}]}]}, {"title": "Change at EOS/ET: Post-bronchodilator FVC", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "533"}, {"groupId": "OG002", "value": "585"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "spread": "0.301"}, {"groupId": "OG001", "value": "0.02", "spread": "0.349"}, {"groupId": "OG002", "value": "0.04", "spread": "0.348"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Raw Forced Expiratory Flow at 25-75 Percent (%) of Pulmonary Volume (FEF25%-75%)", "description": "FEF25%-75% was defined as the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Pre-bronchodilator FEF25%-75% and post-bronchodilator FEF25%-75% are reported for each timepoint. FEF25%-75% was measured using spirometry.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters per second", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "727"}, {"groupId": "OG002", "value": "794"}]}], "classes": [{"title": "Baseline:Pre-bronchodilator FEF25%-75%", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "727"}, {"groupId": "OG002", "value": "794"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.96", "spread": "12.328"}, {"groupId": "OG001", "value": "2.28", "spread": "9.646"}, {"groupId": "OG002", "value": "2.42", "spread": "9.902"}]}]}, {"title": "Change at Month 6:Pre-bronchodilator FEF25%-75%", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "564"}, {"groupId": "OG002", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.66", "spread": "13.518"}, {"groupId": "OG001", "value": "-0.44", "spread": "10.868"}, {"groupId": "OG002", "value": "-0.55", "spread": "11.131"}]}]}, {"title": "Change at EOS/ET:Pre-bronchodilator FEF25%-75%", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "568"}, {"groupId": "OG002", "value": "625"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.69", "spread": "13.426"}, {"groupId": "OG001", "value": "-0.47", "spread": "10.825"}, {"groupId": "OG002", "value": "-0.58", "spread": "11.080"}]}]}, {"title": "Baseline:Post-bronchodilator FEF25%-75%", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "712"}, {"groupId": "OG002", "value": "777"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.76", "spread": "6.676"}, {"groupId": "OG001", "value": "2.58", "spread": "9.503"}, {"groupId": "OG002", "value": "2.68", "spread": "9.302"}]}]}, {"title": "Change at Month 6:Post-bronchodilator FEF25%-75%", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "518"}, {"groupId": "OG002", "value": "571"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.00", "spread": "7.513"}, {"groupId": "OG001", "value": "-0.59", "spread": "11.051"}, {"groupId": "OG002", "value": "-0.63", "spread": "10.767"}]}]}, {"title": "Change at EOS/ET:Post-bronchodilator FEF25%-75%", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "530"}, {"groupId": "OG002", "value": "582"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.76", "spread": "7.515"}, {"groupId": "OG001", "value": "-0.61", "spread": "10.926"}, {"groupId": "OG002", "value": "-0.62", "spread": "10.661"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage Predicted FEV1 (ppFEV1)", "description": "FEV1 is the volume of air that can be forced out in one second after taking a deep breath, as measured using spirometry. Hankinson and Wang standards were used to calculate ppFEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. ppFEV1= 100 multiplied by (\\*) FEV1 (in liters \\[L\\]) divided by (/) predicted FEV1 (in L). Pre-bronchodilator ppFEV1 and post-bronchodilator ppFEV1 are reported for each timepoint.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of predicted FEV1", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "728"}, {"groupId": "OG002", "value": "795"}]}], "classes": [{"title": "Baseline: Pre-bronchodilator ppFEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "728"}, {"groupId": "OG002", "value": "795"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "87.89", "spread": "16.934"}, {"groupId": "OG001", "value": "74.23", "spread": "20.569"}, {"groupId": "OG002", "value": "75.38", "spread": "20.631"}]}]}, {"title": "Change at Month 6: Pre-bronchodilator ppFEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "568"}, {"groupId": "OG002", "value": "626"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.72", "spread": "13.279"}, {"groupId": "OG001", "value": "1.77", "spread": "12.270"}, {"groupId": "OG002", "value": "1.86", "spread": "12.359"}]}]}, {"title": "Change at EOS/ET: Pre-bronchodilator ppFEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "573"}, {"groupId": "OG002", "value": "630"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.00", "spread": "14.713"}, {"groupId": "OG001", "value": "0.91", "spread": "12.922"}, {"groupId": "OG002", "value": "1.37", "spread": "13.163"}]}]}, {"title": "Baseline: Post-bronchodilator ppFEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "713"}, {"groupId": "OG002", "value": "778"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "93.61", "spread": "16.416"}, {"groupId": "OG001", "value": "78.92", "spread": "19.514"}, {"groupId": "OG002", "value": "80.15", "spread": "19.690"}]}]}, {"title": "Change at Month 6: Post-bronchodilator ppFEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "523"}, {"groupId": "OG002", "value": "577"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.09", "spread": "16.398"}, {"groupId": "OG001", "value": "1.47", "spread": "9.617"}, {"groupId": "OG002", "value": "1.52", "spread": "10.421"}]}]}, {"title": "Change at EOS/ET: Post-bronchodilator ppFEV1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "534"}, {"groupId": "OG002", "value": "586"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.39", "spread": "14.673"}, {"groupId": "OG001", "value": "0.82", "spread": "11.099"}, {"groupId": "OG002", "value": "1.40", "spread": "11.597"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Prior Asthma Medications by Category or Class of Medications", "description": "Prior asthma medications were defined as all medications used for asthma prior to the study (initiated within 90 days of baseline) and were assessed retrospectively at baseline. Participants received prior asthma medications of following categories or classes: short acting beta agonist (SABA), combination inhaled corticosteroids/long acting beta agonist (ICS/LABA), leukotriene receptor antagonist (LTRA), inhaled corticosteroids (ICS), oral/parenteral (systemic) corticosteroids, anticholinergic, long acting beta agonist (LABA), and other medication.", "populationDescription": "All enrolled participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "737"}, {"groupId": "OG002", "value": "806"}]}], "classes": [{"title": "All types", "categories": [{"measurements": [{"groupId": "OG000", "value": "98.6"}, {"groupId": "OG001", "value": "99.3"}, {"groupId": "OG002", "value": "99.3"}]}]}, {"title": "SABA", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.3"}, {"groupId": "OG001", "value": "88.6"}, {"groupId": "OG002", "value": "88.8"}]}]}, {"title": "Combination ICS/LABA", "categories": [{"measurements": [{"groupId": "OG000", "value": "79.7"}, {"groupId": "OG001", "value": "84.1"}, {"groupId": "OG002", "value": "83.7"}]}]}, {"title": "LTRA", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.9"}, {"groupId": "OG001", "value": "66.6"}, {"groupId": "OG002", "value": "67.2"}]}]}, {"title": "ICS", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.2"}, {"groupId": "OG001", "value": "33.8"}, {"groupId": "OG002", "value": "34.0"}]}]}, {"title": "Oral/Parenteral (systemic) corticisteroids", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.5"}, {"groupId": "OG001", "value": "31.6"}, {"groupId": "OG002", "value": "31.3"}]}]}, {"title": "Anticholinergic", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.1"}, {"groupId": "OG001", "value": "28.4"}, {"groupId": "OG002", "value": "26.8"}]}]}, {"title": "LABA", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.4"}, {"groupId": "OG001", "value": "4.1"}, {"groupId": "OG002", "value": "3.8"}]}]}, {"title": "Other medication", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.8"}, {"groupId": "OG001", "value": "5.3"}, {"groupId": "OG002", "value": "5.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Concomitant and Ongoing Asthma Medications by Category or Class of Medications", "description": "Concomitant and ongoing asthma medications were defined as all medications used for asthma which began on or after the participant's study start, as well as those ongoing at the beginning of the study. Participants received following categories or classes of concomitant and ongoing asthma medications: SABA, combination ICS/LABA, LTRA, oral/parenteral (systemic) corticosteroids, ICS, anticholinergic, LABA, and other medication.", "populationDescription": "All enrolled participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline until EOS/ET (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "737"}, {"groupId": "OG002", "value": "806"}]}], "classes": [{"title": "All types", "categories": [{"measurements": [{"groupId": "OG000", "value": "100.0"}, {"groupId": "OG001", "value": "99.2"}, {"groupId": "OG002", "value": "99.3"}]}]}, {"title": "SABA", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.3"}, {"groupId": "OG001", "value": "89.4"}, {"groupId": "OG002", "value": "89.6"}]}]}, {"title": "Combination ICS/LABA", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.6"}, {"groupId": "OG001", "value": "82.4"}, {"groupId": "OG002", "value": "82.4"}]}]}, {"title": "LTRA", "categories": [{"measurements": [{"groupId": "OG000", "value": "69.6"}, {"groupId": "OG001", "value": "63.9"}, {"groupId": "OG002", "value": "64.4"}]}]}, {"title": "Oral/Parenteral (systemic) corticosteroids", "categories": [{"measurements": [{"groupId": "OG000", "value": "37.7"}, {"groupId": "OG001", "value": "47.2"}, {"groupId": "OG002", "value": "46.4"}]}]}, {"title": "ICS", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}, {"groupId": "OG001", "value": "34.3"}, {"groupId": "OG002", "value": "34.2"}]}]}, {"title": "Anticholinergic", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.6"}, {"groupId": "OG001", "value": "32.6"}, {"groupId": "OG002", "value": "30.8"}]}]}, {"title": "LABA", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.4"}, {"groupId": "OG001", "value": "4.5"}, {"groupId": "OG002", "value": "4.2"}]}]}, {"title": "Other medication", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.2"}, {"groupId": "OG001", "value": "9.9"}, {"groupId": "OG002", "value": "9.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12) Overall Score", "description": "AQLQ +12 is a 32-item disease specific questionnaire designed to assess the participants' asthma-specific health-related quality of life (QOL). The questionnaire contains four domains: activity limitations (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). All items are scored on a 7-point likert scale. All item scores are averaged to produce one overall QOL score. Overall score ranges from 1 (total impairment) to 7 (no impairment), with higher scores indicating better QOL. A positive change from baseline indicated improved QOL.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "732"}, {"groupId": "OG002", "value": "801"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "732"}, {"groupId": "OG002", "value": "801"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.71", "spread": "1.332"}, {"groupId": "OG001", "value": "3.93", "spread": "1.348"}, {"groupId": "OG002", "value": "4.00", "spread": "1.363"}]}]}, {"title": "Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "593"}, {"groupId": "OG002", "value": "652"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.94", "spread": "1.134"}, {"groupId": "OG001", "value": "1.18", "spread": "1.223"}, {"groupId": "OG002", "value": "1.16", "spread": "1.216"}]}]}, {"title": "Change at EOS/ET", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "603"}, {"groupId": "OG002", "value": "666"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.11", "spread": "1.174"}, {"groupId": "OG001", "value": "1.33", "spread": "1.267"}, {"groupId": "OG002", "value": "1.31", "spread": "1.259"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Test (ACT) Overall Score", "description": "Multidimensional factors associated with asthma control from the participant's perspective were assessed using the ACT questionnaire. The ACT is a validated, five-item patient-reported outcome (PRO) questionnaire that measures the impact of asthma on home and work activities, shortness of breath, symptoms, rescue medication usage, and overall asthma control. All items are scored on a 5-point likert scale (1 to 5). All item scores are added together to calculate a total score. Total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. A positive change from baseline indicated improvement.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Months 3, 6, 9, 12", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "732"}, {"groupId": "OG002", "value": "800"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "732"}, {"groupId": "OG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.40", "spread": "5.117"}, {"groupId": "OG001", "value": "13.71", "spread": "4.910"}, {"groupId": "OG002", "value": "13.94", "spread": "4.981"}]}]}, {"title": "Change at Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "718"}, {"groupId": "OG002", "value": "784"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.11", "spread": "4.141"}, {"groupId": "OG001", "value": "3.58", "spread": "4.263"}, {"groupId": "OG002", "value": "3.54", "spread": "4.252"}]}]}, {"title": "Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "721"}, {"groupId": "OG002", "value": "788"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.57", "spread": "4.339"}, {"groupId": "OG001", "value": "4.16", "spread": "4.677"}, {"groupId": "OG002", "value": "4.11", "spread": "4.649"}]}]}, {"title": "Change at Month 9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "721"}, {"groupId": "OG002", "value": "788"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.90", "spread": "4.844"}, {"groupId": "OG001", "value": "4.39", "spread": "4.910"}, {"groupId": "OG002", "value": "4.35", "spread": "4.903"}]}]}, {"title": "Change at Month 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "721"}, {"groupId": "OG002", "value": "788"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.90", "spread": "4.997"}, {"groupId": "OG001", "value": "4.48", "spread": "4.926"}, {"groupId": "OG002", "value": "4.43", "spread": "4.932"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score", "description": "WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity. A negative change in score indicated improvement and a positive change indicated impairment.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Month 6, EOS/ET (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "717"}, {"groupId": "OG002", "value": "784"}]}], "classes": [{"title": "Work time missed: Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "401"}, {"groupId": "OG002", "value": "404"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.37", "spread": "14.759"}, {"groupId": "OG001", "value": "7.70", "spread": "19.936"}, {"groupId": "OG002", "value": "7.72", "spread": "19.890"}]}]}, {"title": "Work time missed: Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "297"}, {"groupId": "OG002", "value": "298"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}, {"groupId": "OG001", "value": "-3.31", "spread": "19.796"}, {"groupId": "OG002", "value": "-3.30", "spread": "19.763"}]}]}, {"title": "Work time missed: Change at EOS/ET", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "302"}, {"groupId": "OG002", "value": "303"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.27"}, {"groupId": "OG001", "value": "-4.06", "spread": "21.977"}, {"groupId": "OG002", "value": "-4.14", "spread": "21.982"}]}]}, {"title": "Impairment while working: Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "397"}, {"groupId": "OG002", "value": "401"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.00", "spread": "14.142"}, {"groupId": "OG001", "value": "31.36", "spread": "27.111"}, {"groupId": "OG002", "value": "31.15", "spread": "27.087"}]}]}, {"title": "Impairment while working: Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "303"}, {"groupId": "OG002", "value": "305"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.000"}, {"groupId": "OG001", "value": "-16.24", "spread": "26.775"}, {"groupId": "OG002", "value": "-16.13", "spread": "26.719"}]}]}, {"title": "Impairment while working: Change at EOS/ET", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "300"}, {"groupId": "OG002", "value": "301"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-30.00"}, {"groupId": "OG001", "value": "-15.93", "spread": "27.677"}, {"groupId": "OG002", "value": "-15.98", "spread": "27.643"}]}]}, {"title": "Overall WI: Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "387"}, {"groupId": "OG002", "value": "390"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.85", "spread": "25.366"}, {"groupId": "OG001", "value": "33.59", "spread": "28.737"}, {"groupId": "OG002", "value": "33.49", "spread": "28.705"}]}]}, {"title": "Overall WI: Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "284"}, {"groupId": "OG002", "value": "285"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}, {"groupId": "OG001", "value": "-15.55", "spread": "27.476"}, {"groupId": "OG002", "value": "-15.49", "spread": "27.443"}]}]}, {"title": "Overall WI: Change at EOS/ET", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "286"}, {"groupId": "OG002", "value": "287"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-49.09"}, {"groupId": "OG001", "value": "-16.24", "spread": "29.578"}, {"groupId": "OG002", "value": "-16.35", "spread": "29.590"}]}]}, {"title": "Activity impairment: Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "717"}, {"groupId": "OG002", "value": "784"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "36.12", "spread": "27.577"}, {"groupId": "OG001", "value": "48.79", "spread": "28.749"}, {"groupId": "OG002", "value": "47.70", "spread": "28.893"}]}]}, {"title": "Activity impairment: Change at Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "628"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.12", "spread": "33.449"}, {"groupId": "OG001", "value": "-19.30", "spread": "30.445"}, {"groupId": "OG002", "value": "-18.38", "spread": "30.840"}]}]}, {"title": "Activity impairment: Change at EOS/ET", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "577"}, {"groupId": "OG002", "value": "635"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.83", "spread": "31.967"}, {"groupId": "OG001", "value": "-21.40", "spread": "32.424"}, {"groupId": "OG002", "value": "-20.80", "spread": "32.413"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using Global Evaluation of Treatment Effectiveness (GETE) by Inversigator", "description": "Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by investigator, is reported.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "EOS/ET (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "583"}, {"groupId": "OG002", "value": "646"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "81.0"}, {"groupId": "OG001", "value": "75.8"}, {"groupId": "OG002", "value": "76.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using GETE by Participant", "description": "Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by participant, is reported.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "EOS/ET (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "662"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87.3"}, {"groupId": "OG001", "value": "75.0"}, {"groupId": "OG002", "value": "76.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Overall Quality of Life Score", "description": "The MiniRQLQ is a shorter version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) instrument. The MiniRQLQ is a validated quality of life questionnaire to measure the functional impairments that are most troublesome to adult participants with either seasonal or perennial rhinoconjunctivitis of either allergic or non-allergic origin. The miniRQLQ contains 14 items; each item scored on a 7-point scale ranging from 0 \\[not impaired at all\\] to 6 \\[severely impaired\\]). The overall quality of life score is the average of the all item scores and ranges from 0 (not impaired at all) to 6 (severely impaired), with higher scores indicating more impairment. A negative change in score indicated improvement and a positive change indicated impairment.", "populationDescription": "All enrolled participants. Overall number of participants analyzed=participants evaluable for this outcome measure. Here, number analyzed=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, EOS/ET (up to Month 12)", "groups": [{"id": "OG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}, {"id": "OG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "732"}, {"groupId": "OG002", "value": "800"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "732"}, {"groupId": "OG002", "value": "800"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.44", "spread": "1.435"}, {"groupId": "OG001", "value": "2.76", "spread": "1.375"}, {"groupId": "OG002", "value": "2.73", "spread": "1.382"}]}]}, {"title": "Change at EOS/ET", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "659"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.17", "spread": "1.357"}, {"groupId": "OG001", "value": "-0.99", "spread": "1.307"}, {"groupId": "OG002", "value": "-1.01", "spread": "1.311"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "From signing of informed consent form to 28 days after participants last visit (up to approximately 1 year)", "description": "Safety evaluable participants defined as those who received at least 1 dose of omalizumab at any point in the study. Safety events collected and recorded during the study were: all serious adverse events, nonserious AEs of special interest, pregnancies, and nonserious AEs causally related to a Genentech product or where causality is unknown. Additional AEs not meeting the protocol-specified criteria listed above were reported during the study and were included in the safety database.", "eventGroups": [{"id": "EG000", "title": "Participants With Allergic Asthma (Age 12-17 Years)", "description": "Adolescent participants (age 12-17 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.", "seriousNumAffected": 5, "seriousNumAtRisk": 69, "otherNumAffected": 9, "otherNumAtRisk": 69}, {"id": "EG001", "title": "Participants With Allergic Asthma (Age >/=18 Years)", "description": "Adult participants (age \\>/=18 years) with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.", "seriousNumAffected": 85, "seriousNumAtRisk": 732, "otherNumAffected": 58, "otherNumAtRisk": 732}, {"id": "EG002", "title": "Total Participants With Allergic Asthma", "description": "All participants with allergic asthma, who had decided to initiate treatment with omalizumab were observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurred first.", "seriousNumAffected": 90, "seriousNumAtRisk": 801, "otherNumAffected": 67, "otherNumAtRisk": 801}], "seriousEvents": [{"term": "Acute left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Coronary artery thrombosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Allergic granulomatous angiitis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 801}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Gastrointestinal viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Tubo-ovarian abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Helicobacter test positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Fluid retention", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Intervertebral disc displacement", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Osteoporotic fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Malignant glioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Non-Hodgkin's lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Ovarian epithelial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Cerebellar haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Hemiparesis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Intracranial aneurysm", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Pelvic adhesions", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 26, "numAtRisk": 801}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 801}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 801}]}, {"term": "Status asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 801}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Mastectomy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Muscle operation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Embolism", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Peripheral embolism", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}], "otherEvents": [{"term": "Hypothyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Paraesthesia oral", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Injection site pruritus", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Injection site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Local reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Serum sickness", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Mononucleosis syndrome", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pneumonia mycoplasmal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pelvic fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Hypertriglyceridaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Bone pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Thyroid cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 801}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Bronchial secretion retention", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Pneumothorax spontaneous", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Respiratory tract congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Sputum increased", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 801}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 801}]}, {"term": "Acne", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Rash erythematous", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Rash pruritic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Urticaria chronic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Foot operation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Hernia hiatus repair", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Hip arthroplasty", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Meningioma surgery", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Rotator cuff repair", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Skin graft", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 801}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 732}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 801}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This study was designed as an observational registry of participants with allergic asthma; but, was later reclassified as an interventional trial because the protocol was amended to include blood draws that were not considered to be standard of care."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."}, "pointOfContact": {"title": "Medical Communications", "organization": "Hoffmann-La Roche", "email": "genentech@druginfo.com", "phone": "800-821-8590"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}